Method of diagnosing Alzheimer's disease
OwnerChaovanee Aroonsakulinventor
Life of this patent
Estimating the term…
Abstract
A method of diagnosing Alzheimer's disease by the determination of the levels of the hormones somatotropin (human growth hormone) and somatomedin-C (IGF-I) after the administration of the L-dopa provocative test. Blood-sera samples are taken every thirty minutes for a two hour period after the administration of L-dopa, and the samples are tested for the levels of these hormones. These levels are then compared against the levels for normal subjects in the age group of between fifty and sixty. If the levels of the patient being diagnosed falls below the statistical mean corrected for error, then a diagnosis of Alzheimer's disease is indicated.
Claims21
A method of diagnosing Alzheimer's disease in human beings comprising the steps of;
- (a) subjecting a patient suspected of suffering from Alzheimer's disease to a somatotropin secretion-stimulation test;
- (b) determining the levels of somatotropin in at least one blood serum sample taken from the patient after the somatotropin secretion-stimulation test;
- and
- (c) comparing the levels of somatotropin from the at least one blood serum sample, obtained during said step (b) with the levels of somatotropin found in normal subjects within the patient's age group to determine if any increases of somatotropin caused by said step (a) statistically-match the increases thereof found in normal subjects.
A method of diagnosing Alzheimer's disease, in which the L-dopa provocative test, or the equivalent thereof, has been given the patient being diagnosed, comprising:
- (a) determining the levels of at least one of the hormones somatotropin and somatomedin-C after the administration of the L-dopa, or the equivalent thereof;
- and
- (b) comparing the levels of at least one of somatotropin and somatomedin-C obtained from step (a) with levels of normal subjects within the same age bracket as the patient being tested for Alzheimer's disease, in order to determine if any increase, or lack thereof, in the levels from said step (a) falls below the statistical levels of the normal subjects.
A method of diagnosing Alzheimer's disease comprising the steps of:
- (a) stimulating the secretion of somatotropin and somatomedin-C in a patient suspected of suffering from Alzheimer's disease;
- (b) determining the levels of somatotropin and somatomedin-C in at least one blood serum sample taken from the patient after step (a) has been performed;
- and
- (c) comparing the levels of somatotropin and somatomedin-C determined in step (b) to typical levels of somatotropin and somatomedin-C found in subjects who do not suffer from Alzheimer's disease of like age to the patient.
Dependencies are inferred from the claim text.